Antibody-Labelled PSA and hK2 Imaging for Prostate Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for prostate cancer often struggle to distinguish it from other prostate complications like benign prostatic hyperplasia and prostatitis, as they rely on PSA measurements that can be elevated in all conditions, leading to the need for invasive biopsies which are painful, risky, and can result in erroneous diagnoses.
Innovation Solution
A diagnostic method using tracer-labelled PSA and hK2 specific antibodies for visualizing PSA and hK2 producing tissues through PET scans or other radiologic methods, allowing for differentiation between prostate cancer and other prostate disorders without the need for biopsies, and enabling investigation of metastasis and treatment monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA measurement is used for diagnosis, then prostate cancer can be detected, but it cannot be distinguished from other prostate complications like BPH and prostatitis
Solution Approach 1:
The patent divides the diagnostic approach into two separate antibody targets: PSA-specific antibodies and hK2-specific antibodies. By segmenting the diagnostic markers and measuring them separately, the method can distinguish between different prostate conditions based on the specific pattern of antibody binding, thereby resolving the inability to differentiate diseases that plagued single-marker PSA diagnosis.
Solution Approach 2:
The patent introduces a new diagnostic parameter (hK2 antibody binding) in addition to the existing PSA parameter. By changing the diagnostic approach from a single parameter to multiple parameters, the method enables differentiation between prostate cancer, BPH, and prostatitis based on the combined antibody binding patterns, thus improving diagnostic accuracy without losing disease-specific information.
2Measurement precision
If biopsy is performed to verify prostate cancer, then accurate diagnosis can be obtained, but it causes pain, discomfort, and various risks to patients
Solution Approach 1:
The patent replaces the mechanical invasive procedure of biopsy with a non-invasive immunodetection method using antibody binding assays. This substitution eliminates the need for physical tissue sampling, thereby removing the associated pain, discomfort, and surgical risks while maintaining diagnostic verification accuracy through the specific antibody binding patterns that identify cancerous tissue.
Solution Approach 2:
The patent introduces antibody-tracer complexes as intermediaries that can specifically bind to and identify cancerous prostate tissue without requiring direct physical contact or tissue removal. These intermediary agents carry diagnostic information back to the detector, enabling accurate verification of prostate cancer through a non-invasive blood or urine test rather than mechanical biopsy.
3Reliability
If biopsy is performed, then prostate cancer can be confirmed, but PSA concentration increases after biopsy due to damaged cell structure
Solution Approach 1:
The patent performs the antibody binding measurement before any invasive procedure that could damage tissue and release PSA. By conducting the immunodetection assay preliminarily, the method captures the baseline PSA and hK2 antibody binding patterns without the confounding effect of procedure-induced PSA release, thereby maintaining reliable cancer confirmation while avoiding artificial PSA concentration increases.
Solution Approach 2:
The patent uses antibody-tracer complexes that bind to and copy the diagnostic information from prostate tissue markers without requiring physical disruption of the tissue. This informational copying mechanism allows cancer confirmation through molecular recognition rather than mechanical tissue destruction, thereby preventing the secondary effect of increased PSA release that occurs with traditional biopsy.
4Productivity
If biopsy is performed repeatedly, then monitoring can be performed, but scars form that alter prostate tissue structure and make future biopsies difficult
Solution Approach 1:
The patent replaces the mechanical biopsy procedure with a non-invasive immunodetection method using antibody binding assays. This substitution eliminates the tissue-damaging mechanical process while maintaining the ability to monitor prostate health over time. The method can be repeated indefinitely without creating scars or altering tissue structure, thereby preserving future monitoring capability.
Solution Approach 2:
The patent enables the prostate tissue to effectively 'self-report' its condition through the natural expression of PSA and hK2 markers that can be detected in blood or urine. This self-service diagnostic approach eliminates the need for external mechanical intervention (biopsy) that causes scarring, allowing continuous monitoring without compromising future access to the tissue or altering its structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables accurate diagnosis and differentiation of prostate cancer from other prostate issues, reducing the need for biopsies and associated risks, while allowing for effective monitoring of metastasis and treatment outcomes.
Implementation Method 1
visualisation of PSA and/or hK2 producing tissue with tracer-labelled PSA and hK2 specific antibodies
Implementation Method 2
visualizing PSA and hK2 producing tissues through PET scans or other radiologic methods
Implementation Method 3
tracer-labelled PSA and hK2 specific antibodies
Data Source
AI summary
Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualization method, and diagnosing prostate cancer from the difference in visualization.